NCT01136174 - Safety and PK Study of BIBF 1120 in Japanese Patients With IPF | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

March 31, 2011

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG

Placebo

Placebo BID for cohort 1,2,3

DRUG

BIBF 1120

50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively

DRUG

BIBF 1120

50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively

DRUG

BIBF 1120

50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively

Trial Locations (8)

1199.31.002 Boehringer Ingelheim Investigational Site, Bunkyo-ku,Tokyo

1199.31.004 Boehringer Ingelheim Investigational Site, Hamamatsu, Shizuoka

1199.31.008 Boehringer Ingelheim Investigational Site, Himeji, Hyogo

1199.31.006 Boehringer Ingelheim Investigational Site, Nagoya, Aichi

1199.31.007 Boehringer Ingelheim Investigational Site, Sakai, Osaka

1199.31.005 Boehringer Ingelheim Investigational Site, Seto, Aichi

1199.31.001 Boehringer Ingelheim Investigational Site, Shimotsuke,Tochigi

1199.31.003 Boehringer Ingelheim Investigational Site, Yokohama, Kanagawa